Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

General Counsel and Secretary

Chief R&D Officer

President and CEO

Chief Commercial Officer

Chief Medical Officer

Chief Technical Officer

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune di...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-04	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-29	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-09	Premium	sold	Premium	Premium	Premium	General Counsel and Secretary
2024-01-09	Premium	sold	Premium	Premium	Premium	Chief R&D Officer
2024-01-09	Premium	sold	Premium	Premium	Premium	President and CEO
2024-01-09	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-01-02	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-26	Premium	bought	Premium	Premium	Premium	-
2023-12-26	Premium	sold	Premium	Premium	Premium	-
2023-12-18	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-11-09	Premium	sold	Premium	Premium	Premium	General Counsel and Secretary
2023-08-18	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-08-04	Premium	sold	Premium	Premium	Premium	-
2023-07-05	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-07-05	Premium	sold	Premium	Premium	Premium	Chief Commercial Officer
2023-06-14	Premium	sold	Premium	Premium	Premium	-
2023-04-21	Premium	bought	Premium	Premium	Premium	-
2023-04-20	Premium	bought	Premium	Premium	Premium	-
2023-04-18	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-04-14	Premium	sold	Premium	Premium	Premium	-
2023-04-14	Premium	bought	Premium	Premium	Premium	-
2023-04-14	Premium	sold	Premium	Premium	Premium	-
2023-04-13	Premium	acquired	Premium	Premium	Premium	-
2023-01-19	Premium	acquired	Premium	Premium	Premium	-
2023-01-13	Premium	bought	Premium	Premium	Premium	-

FATE - Fate Therapeutics Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for FATE